Sign Up to like & get
recommendations!
1
Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.37_2629
Abstract: Karyopharm Therapeutics, Kite Pharma, Lundbeck, Merck, Roche/Genentech, Inc., Seattle Genetics, Takeda, Teva, TG Therapeutics; Research Funding: Roche/Genentech, Inc. Sharman, J: Consultant Advisory Role: Pharmacyclics, Celgene, TG Therapeutics, Genentech, Inc., AbbVie, Acerta Pharma/AstraZeneca; Research Funding: Pharmacyclics,…
read more here.
Keywords:
gilead sciences;
study;
genentech inc;
oncology ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Ophthalmology"
DOI: 10.1016/j.ophtha.2017.11.022
Abstract: Originally received: March 28, 2017. Final revision: July 21, 2017. Accepted: August 30, 2017. Available online: October 27, 2017. Manuscript no. 2017-714. 1 Department of Ophthalmology, University of Bonn, Bonn, Germany. 2 Department of Ophthalmology…
read more here.
Keywords:
new york;
roche;
ophthalmology;
genentech inc ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.1838
Abstract: Background Patients with rheumatoid arthritis (RA) often receive methotrexate (MTX) in combination with biologics; however, MTX may be discontinued due to intolerance or to reduce the medication burden once disease control is achieved. Whereas previous…
read more here.
Keywords:
genentech inc;
week;
mtx;
tcz mtx ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-116038
Abstract: Introduction The measurement, analysis, and communication of treatment-related symptoms and their impact on the functioning of individuals in clinical trials is an area of interest to the medical community, the Food and Drug Administration and…
read more here.
Keywords:
phase;
treatment;
gas;
genentech inc ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2021 at "Diabetes"
DOI: 10.2337/db21-86-or
Abstract: The leading cause of vision loss in people with diabetic retinopathy (DR) is DME. Intravitreal anti-VEGF therapy is the standard of care for DME; however, optimal vision outcomes are difficult to achieve, and the need…
read more here.
Keywords:
employee;
self genentech;
roche pharma;
dme ... See more keywords